FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%

Matthew Durham
Omnidynamic Marketing

David Linetsky
Point-of-Care Marketing

Bud Bilanich
Success Coach

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

Stacey Gandler
Brand Nourishment

Amy Giles
Increasing Engagement

Joey Cohen
Medication Adherence

Paul Theisen
Patient Acquisition

Matt Turner
Patient Affordability

Suma Ramadas, PhD
Medical Affairs

Frank Burrell
Scientific Storytelling

Liz Kane
Impactful Strategy

Brenda Snow
Authentic Patient Voice